Elevated Fecal Lactoferrin: Clinical Interpretation and Management

Understanding This Result

Fecal lactoferrin has 83% sensitivity and 75% specificity for detecting moderate to severe endoscopic inflammation in inflammatory bowel disease, meaning this elevated result strongly suggests active mucosal inflammation 2, 4

Stool culture for bacterial pathogens (Salmonella, Shigella, Campylobacter, E. coli O157:H7) should be performed to rule out infectious causes 5
C. difficile toxin testing should be done to exclude enteric infections 5, 6
Fecal calprotectin measurement provides a quantitative assessment and helps establish which biomarker correlates better with the disease pattern 1, 2, 6
Serum C-reactive protein (CRP) elevation >5 mg/L has moderate certainty of evidence for ruling in moderate to severe endoscopic inflammation 2, 7

The American Gastroenterological Association recommends endoscopic assessment rather than empiric treatment when biomarkers are elevated, regardless of symptom severity 4
Early endoscopy within 7-14 days of symptom onset is associated with shorter symptom duration and shorter steroid treatment duration compared to delayed endoscopy 5
Colonoscopy with ileoscopy and biopsy is the gold standard for establishing diagnosis and assessing disease extent 1, 2
The National Comprehensive Cancer Network specifically recommends early endoscopy for all patients with positive lactoferrin results, even those with only mild symptoms 5

With moderate to severe symptoms and elevated lactoferrin, the false positive rate is only 4.6%, meaning 95.4% of patients truly have moderate to severe endoscopic inflammation 6
Endoscopic assessment is still recommended rather than empiric treatment adjustment to establish diagnosis and guide therapy 4

Repeat fecal calprotectin 2-4 months after starting or adjusting therapy to monitor treatment response 6
Both calprotectin and lactoferrin decline significantly with successful anti-TNF therapy, so serial measurements help guide management 6